DK1653964T3 - Cancerkombinationsterapi omfattende AZD2171 og ZD1839 - Google Patents

Cancerkombinationsterapi omfattende AZD2171 og ZD1839

Info

Publication number
DK1653964T3
DK1653964T3 DK04743287T DK04743287T DK1653964T3 DK 1653964 T3 DK1653964 T3 DK 1653964T3 DK 04743287 T DK04743287 T DK 04743287T DK 04743287 T DK04743287 T DK 04743287T DK 1653964 T3 DK1653964 T3 DK 1653964T3
Authority
DK
Denmark
Prior art keywords
azd2171
human
combination therapy
cancer
antiangiogenic
Prior art date
Application number
DK04743287T
Other languages
Danish (da)
English (en)
Inventor
Stephen Robert Wedge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1653964T3 publication Critical patent/DK1653964T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK04743287T 2003-07-10 2004-07-08 Cancerkombinationsterapi omfattende AZD2171 og ZD1839 DK1653964T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0316127.0A GB0316127D0 (en) 2003-07-10 2003-07-10 Combination therapy
PCT/GB2004/002944 WO2005004872A1 (en) 2003-07-10 2004-07-08 Cancer combination therapy comprising azd2171 and zd1839

Publications (1)

Publication Number Publication Date
DK1653964T3 true DK1653964T3 (da) 2009-01-05

Family

ID=27741907

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04743287T DK1653964T3 (da) 2003-07-10 2004-07-08 Cancerkombinationsterapi omfattende AZD2171 og ZD1839

Country Status (23)

Country Link
US (2) US20060167024A1 (de)
EP (1) EP1653964B1 (de)
JP (1) JP2007526888A (de)
KR (1) KR20060033785A (de)
CN (1) CN100415236C (de)
AT (1) ATE409039T1 (de)
AU (1) AU2004255024B2 (de)
BR (1) BRPI0412408A (de)
CA (1) CA2531620C (de)
DE (1) DE602004016754D1 (de)
DK (1) DK1653964T3 (de)
ES (1) ES2313033T3 (de)
GB (1) GB0316127D0 (de)
HR (1) HRP20080597T3 (de)
IL (1) IL172683A0 (de)
MX (1) MXPA06000412A (de)
NO (1) NO20056170L (de)
NZ (1) NZ544270A (de)
PL (1) PL1653964T3 (de)
PT (1) PT1653964E (de)
SI (1) SI1653964T1 (de)
WO (1) WO2005004872A1 (de)
ZA (1) ZA200600184B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
US20080113039A1 (en) * 2004-03-23 2008-05-15 Stephen Robert Wedge Combination Therapy
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
WO2007003933A2 (en) * 2005-07-06 2007-01-11 Astrazeneca Ab Combination therapy of cancer with azd2171 and gemcitabine
CA2631676A1 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of azd2171 and pemetrexed
WO2009118560A1 (en) * 2008-03-28 2009-10-01 Astrazeneca Ab Combination therapy 038
EP2113255A1 (de) * 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Zytotoxisches Immunglobulin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002518341A (ja) * 1998-06-15 2002-06-25 アーチ・デヴェロップメント・コーポレイション 放射線療法と抗血管形成因子の組み合わせ
BRPI0017548B8 (pt) * 1999-02-10 2023-05-02 Astrazeneca Ab Composto
DE60111622T2 (de) * 2000-03-31 2006-05-18 Angiogene Pharmaceuticals Ltd. Getrennte dosis therapien mit gefässschädigender aktivität
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
AU2002223684A1 (en) * 2000-11-22 2002-06-03 Novartis Pharma Gmbh Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
CN1625555A (zh) * 2002-02-01 2005-06-08 阿斯特拉曾尼卡有限公司 喹唑啉化合物

Also Published As

Publication number Publication date
CN1819831A (zh) 2006-08-16
PT1653964E (pt) 2008-11-24
AU2004255024A1 (en) 2005-01-20
WO2005004872A1 (en) 2005-01-20
DE602004016754D1 (de) 2008-11-06
KR20060033785A (ko) 2006-04-19
CA2531620A1 (en) 2005-01-20
AU2004255024B2 (en) 2007-09-27
SI1653964T1 (sl) 2009-02-28
CN100415236C (zh) 2008-09-03
ES2313033T3 (es) 2009-03-01
EP1653964B1 (de) 2008-09-24
BRPI0412408A (pt) 2006-08-22
ATE409039T1 (de) 2008-10-15
JP2007526888A (ja) 2007-09-20
HRP20080597T3 (en) 2008-12-31
CA2531620C (en) 2011-09-27
NO20056170L (no) 2006-02-08
EP1653964A1 (de) 2006-05-10
MXPA06000412A (es) 2006-03-17
US20060167024A1 (en) 2006-07-27
HK1089667A1 (en) 2006-12-08
NZ544270A (en) 2007-09-28
GB0316127D0 (en) 2003-08-13
IL172683A0 (en) 2006-04-10
US20100179142A1 (en) 2010-07-15
ZA200600184B (en) 2007-04-25
PL1653964T3 (pl) 2009-01-30

Similar Documents

Publication Publication Date Title
GB0223380D0 (en) Combination therapy
NO20082567L (no) Kombinasjon av ZD6474 og pemetrexed
MXPA04004355A (es) Tratamiento de combinacion que comprende zd6474 y un taxano.
CY1111482T1 (el) Συνδυασμος azd2171 και πεμετρεξεδης
MX2007003506A (es) Terapia de combinacion de cancer que comprende azd2171 e imatinib.
MX2007003505A (es) Combinacion que comprende zd6474 e imatinib.
MXPA05008583A (es) Terapia de combinacion de zd6474 con 5-fu y/o cpt-11.
PL1653964T3 (pl) Skojarzone leczenie raka obejmujące AZD2171 i ZD1839
NO20064755L (no) Kombinasjonsterapi
NO20056171L (no) Kombinasjonsterapi
NO20064754L (no) Kombinasjonsterapi
WO2005092384A3 (en) Combination therapy with azd2171 and a platinum anti-tumour agent
NO20051601L (no) Kombinasjonsterapi med gemcitabin og zd6126